$41.6
Live
Insights on Iradimed Corp
Revenue is up for the last 15 quarters, 6.79M → 17.45M (in $), with an average increase of 6.5% per quarter
Netprofit is down for the last 2 quarters, 5.06M → 4.53M (in $), with an average decrease of 10.4% per quarter
In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 37.1%
In the last 3 years, Boston Scientific Corp. has given 70.6% return, outperforming this stock by 9.1%
0.58%
Downside
Day's Volatility :1.87%
Upside
1.3%
13.75%
Downside
52 Weeks Volatility :29.23%
Upside
17.95%
Period | Iradimed Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.76% | 1.7% | 0.0% |
6 Months | 8.85% | 11.3% | 0.0% |
1 Year | 5.6% | 5.4% | 1.3% |
3 Years | 60.64% | 13.9% | -22.1% |
Market Capitalization | 526.8M |
Book Value | $5.64 |
Dividend Share | 0.15 |
Dividend Yield | 0.36% |
Earnings Per Share (EPS) | 1.35 |
PE Ratio | 30.81 |
PEG Ratio | 4.46 |
Wall Street Target Price | 62.5 |
Profit Margin | 26.22% |
Operating Margin TTM | 29.57% |
Return On Assets TTM | 14.1% |
Return On Equity TTM | 23.7% |
Revenue TTM | 65.6M |
Revenue Per Share TTM | 5.2 |
Quarterly Revenue Growth YOY | 17.4% |
Gross Profit TTM | 41.3M |
EBITDA | 20.8M |
Diluted Eps TTM | 1.35 |
Quarterly Earnings Growth YOY | 0.23 |
EPS Estimate Current Year | 1.52 |
EPS Estimate Next Year | 1.71 |
EPS Estimate Current Quarter | 0.4 |
EPS Estimate Next Quarter | 0.41 |
What analysts predicted
Upside of 50.24%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 30.4M | ↑ 31.88% |
Net Income | 6.3M | ↑ 1161.29% |
Net Profit Margin | 20.71% | ↑ 18.54% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 38.5M | ↑ 26.54% |
Net Income | 9.6M | ↑ 52.79% |
Net Profit Margin | 25.0% | ↑ 4.29% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 31.7M | ↓ 17.65% |
Net Income | 1.4M | ↓ 85.79% |
Net Profit Margin | 4.32% | ↓ 20.68% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 41.8M | ↑ 31.83% |
Net Income | 9.3M | ↑ 581.19% |
Net Profit Margin | 22.3% | ↑ 17.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 53.3M | ↑ 27.48% |
Net Income | 12.8M | ↑ 37.55% |
Net Profit Margin | 24.06% | ↑ 1.76% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 65.6M | ↑ 23.0% |
Net Income | 17.2M | ↑ 34.03% |
Net Profit Margin | 26.22% | ↑ 2.16% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.4M | ↑ 5.39% |
Net Income | 3.4M | ↑ 5.74% |
Net Profit Margin | 25.56% | ↑ 0.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 14.9M | ↑ 10.86% |
Net Income | 3.7M | ↑ 7.19% |
Net Profit Margin | 24.72% | ↓ 0.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.5M | ↑ 4.11% |
Net Income | 3.4M | ↓ 7.28% |
Net Profit Margin | 22.01% | ↓ 2.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.1M | ↑ 4.23% |
Net Income | 4.2M | ↑ 22.72% |
Net Profit Margin | 25.91% | ↑ 3.9% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.5M | ↑ 2.32% |
Net Income | 5.1M | ↑ 21.23% |
Net Profit Margin | 30.7% | ↑ 4.79% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.5M | ↑ 5.74% |
Net Income | 4.5M | ↓ 10.41% |
Net Profit Margin | 26.01% | ↓ 4.69% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 48.4M | ↑ 24.17% |
Total Liabilities | 6.5M | ↑ 6.82% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 66.7M | ↑ 37.75% |
Total Liabilities | 11.2M | ↑ 72.47% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 71.1M | ↑ 6.5% |
Total Liabilities | 9.7M | ↓ 13.59% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 82.9M | ↑ 16.62% |
Total Liabilities | 10.7M | ↑ 10.59% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 85.5M | ↑ 3.17% |
Total Liabilities | 11.8M | ↑ 10.58% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 92.2M | ↑ 7.77% |
Total Liabilities | 20.7M | ↑ 75.12% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 79.5M | ↑ 5.05% |
Total Liabilities | 9.8M | ↓ 0.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 85.5M | ↑ 7.5% |
Total Liabilities | 11.8M | ↑ 21.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 75.6M | ↓ 11.57% |
Total Liabilities | 11.3M | ↓ 4.73% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 81.4M | ↑ 7.68% |
Total Liabilities | 12.4M | ↑ 10.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 87.4M | ↑ 7.34% |
Total Liabilities | 12.8M | ↑ 3.26% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 92.2M | ↑ 5.43% |
Total Liabilities | 20.7M | ↑ 61.52% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 7.4M | ↑ 115.93% |
Investing Cash Flow | 1.5M | ↓ 248.1% |
Financing Cash Flow | 929.9K | ↓ 148.93% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.2M | ↑ 38.73% |
Investing Cash Flow | 3.2M | ↑ 111.18% |
Financing Cash Flow | 2.0M | ↑ 117.25% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.8M | ↓ 43.15% |
Investing Cash Flow | 247.0K | ↓ 92.29% |
Financing Cash Flow | 522.5K | ↓ 74.14% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.3M | ↑ 93.52% |
Investing Cash Flow | 648.2K | ↑ 162.48% |
Financing Cash Flow | 24.4K | ↓ 95.33% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.0M | ↓ 10.8% |
Investing Cash Flow | -1.4M | ↓ 312.11% |
Financing Cash Flow | -12.7M | ↓ 52122.11% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.9M | ↑ 140.26% |
Investing Cash Flow | -556.2K | ↓ 817.1% |
Financing Cash Flow | 52.3K | ↓ 1014.25% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.0M | ↓ 22.84% |
Investing Cash Flow | -471.7K | ↓ 15.19% |
Financing Cash Flow | -198.5K | ↓ 479.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.6M | ↑ 52.89% |
Investing Cash Flow | -6.6M | ↑ 1290.15% |
Financing Cash Flow | -13.3M | ↑ 6587.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.5M | ↓ 24.37% |
Investing Cash Flow | -378.3K | ↓ 94.23% |
Financing Cash Flow | -89.8K | ↓ 99.32% |
Sell
Neutral
Buy
Iradimed Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Iradimed Corp | -1.19% | 8.85% | 5.6% | 60.64% | 46.8% |
Stryker Corporation | -4.04% | 30.03% | 12.47% | 26.98% | 79.97% |
Dexcom, Inc. | -1.59% | 63.45% | 11.22% | 31.69% | 366.88% |
Boston Scientific Corp. | 8.35% | 45.85% | 42.65% | 72.49% | 97.43% |
Abbott Laboratories | -2.84% | 14.24% | -2.8% | -12.8% | 36.85% |
Medtronic Plc | -3.44% | 12.58% | -10.38% | -38.23% | -7.46% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Iradimed Corp | 30.81 | 30.81 | 4.46 | 1.52 | 0.24 | 0.14 | 0.0 | 5.64 |
Stryker Corporation | 40.64 | 40.64 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Dexcom, Inc. | 102.89 | 102.89 | 2.53 | 1.76 | 0.26 | 0.06 | NA | 5.37 |
Boston Scientific Corp. | 64.48 | 64.48 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Abbott Laboratories | 33.52 | 33.52 | 5.99 | 4.31 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.81 | 25.81 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Iradimed Corp | Buy | $526.8M | 46.8% | 30.81 | 26.22% |
Stryker Corporation | Buy | $127.4B | 79.97% | 40.64 | 15.44% |
Dexcom, Inc. | Buy | $54.6B | 366.88% | 102.89 | 14.95% |
Boston Scientific Corp. | Buy | $101.4B | 97.43% | 64.48 | 11.18% |
Abbott Laboratories | Buy | $186.7B | 36.85% | 33.52 | 13.96% |
Medtronic Plc | Buy | $107.9B | -7.46% | 25.81 | 13.0% |
Nine Ten Capital Management LLC
BlackRock Inc
Soleus Capital Management, L.P.
Renaissance Technologies Corp
Vanguard Group Inc
Rk Capital Management, LLC
iradimed corporation develops, manufactures, markets, and distributes magnetic resonance imaging (mri) compatible medical devices, and related accessories and services in the united states and internationally. it offers mri compatible intravenous (iv) infusion pump system with associated disposable iv tubing sets; and mri compatible patient vital signs monitoring system. the company also provides iv poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and spo2 monitoring with sensors and accessories. it serves hospitals, acute care facilities, and outpatient imaging centers. the company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. iradimed corporation was incorporated in 1992 and is headquartered in winter springs, florida.
Organization | Iradimed Corp |
Employees | 148 |
CEO | Mr. Roger E. Susi |
Industry | Health Technology |